C5 and age-related macular degeneration: Other anti-C5 antibodies have also been developed and are currently in clinical trials, such as tesidolumab, also known as LFG316, which is undergoing testing for AMD (NCT01527500), PNH (NCT02534909) and non-infectious intermediate, posterior or panuveitis (NIIPPU) (NCT01526889); ravulizumab, also called ALXN1210, is in phase 3 clinical trials for PNH (NCT03056040), substituting in the treatment for eculizumab, with results not inferior to eculizumab [61].